Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method

Food and Healthcare Press Releases Friday August 11, 2017 15:23
ANN ARBOR, Michigan--11 Aug--PRNewswire/InfoQuest
Study published in Science magazine demonstrates how epigenetic markers can identify cell subtypes and regulatory elements that drive cellular diversity

Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing (NGS), today announced the launch of a new single-cell methylation sequencing method based on its Accel-NGS(R) Adaptase(TM) technology , an efficient and robust NGS-prep solution for whole-genome bisulfite sequencing at single-cell resolution. This new method enables the efficient analysis of different methylated regions across thousands of cells from heterogeneous tissues, while also addressing applications, such as cell classification, regulation of cellular mechanisms in normal tissue, epigenetic alterations in disease states and evolutionary conservation of epigenomic regulation.

Methylation is a stable biomarker that can be used to identify cell types and the regulatory elements underlying cell function. When coupled with single-cell RNA expression studies, single-cell methylation can elucidate the regulatory elements, in turn controlling the unique expression profiles of individual cells and differences between cells. Additionally, recent clinical studies have uncovered methylation patterns in diseases—such as cancer—which identify tumor type, assess tumor burden in liquid biopsies, and correlate with disease progression, prognosis and drug response.

This method was recently described in the Science paper entitled " Single Cell Methylomes Identify Neuronal Subtypes and Regulatory Elements in Mammalian Cortex " by collaborators at the Salk Institute, University of California San Diego and Swift Biosciences. The workflow combines fluorescence-activated cell sorting-based isolation, bisulfite conversion and Swift's Accel-NGS Adaptase module with other commercially available components. The published results demonstrated a greater than two-fold increase in read-mapping rates as compared to other methods; thereby, significantly improving the data output per sequencing run while reducing the overall cost.

"This is one of many scientific collaboration in which Swift technologies is pushing the boundaries of science," said Timothy Harkins, president and CEO of Swift Biosciences and co-author on the paper. "We are excited about new insights into basic cellular processes, and the profound, future impact it will have on precision medicine."

"Our proprietary Adaptase technology constructs high-complexity NGS libraries from low-input, single-stranded DNA," said Laurie Kurihara, PhD, senior director of research and development and co-author on the paper. "Our single-cell workflow has fewer steps than other methods and offers multiplexed, single-cell processing to provide greater productivity for high-throughput applications."

The Accel-NGS Adaptase Module is now commercially available.

Latest Press Release

#Sitting is the new Smoking dont be a health statistic! Join the BodyConscious FREE seminar to help you overcome Office Syndrome

Ever suffer from headache, sore eyes, back pain, stiff neck, muscle tension or headaches? Those long hours hunched over a computer could be the problem. More than 60% of office workers in Thailand seek medical treatment for Office Syndrome, which causes...

Medical Devices ASEAN 2018 supports the push to position Thailand as the medical hub of Asia

Medical Devices ASEAN 2018 ("MDA 2018") – the international exhibition and academic congress on medical devices, technologies, services and general healthcare – opens today and runs until Friday, 13 July 2018 at Hall 1-2, IMPACT Exhibition...

Berlinger Group Presents Arrangements for the Future Provision of Its World-renowned Anti-doping Products

- Distribution and further development of Berlinger anti-doping products to be entrusted to a foundation; Berlinger Board of Directors appoints new Group CEO The Swiss-based Berlinger Group (which comprises Berlinger & Co. AG and Berlinger Special...

Ideal Cures Launches Two New Film Coating Products INSTACOAT QD and INSTACOAT T2F at the 2nd FDD Conclave

Ideal Cures, an Indian company headquartered in Mumbai, India, launched two new ready-to-use film coating products INSTACOAT QD and INSTACOAT T2F, at the 2nd Formulation and Drug Delivery Conclave (FDD), held on 15th-16th June 2018, at Hyderabad, India...

A Century After Umami#s Discovery, Its Benefits Continue to Expand

Umami, known as the savory taste, was discovered more than a century ago, yet recent research continues to document the benefits of umami. Currently underway is a year-long recognition of umami's 110th anniversary since its discovery in 1908. At one...

Related Topics